Development of novel self‐assembled vaccines based on tumour‐specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via …
W Shi, Z Tong, S Chen, Q Qiu, J Zhou, H Qian - Immunology, 2023 - Wiley Online Library
Vaccines based on tumour‐specific antigens are a promising approach for immunotherapy.
However, the clinical efficacy of tumour‐specific antigens is still challenging. Twelve …
However, the clinical efficacy of tumour‐specific antigens is still challenging. Twelve …
Development of novel self-assembled vaccines based on tumour-specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via activating …
W Shi, Z Tong, S Chen, Q Qiu, J Zhou, H Qian - Immunology, 2023 - europepmc.org
Vaccines based on tumour-specific antigens are a promising approach for immunotherapy.
However, the clinical efficacy of tumour-specific antigens is still challenging. Twelve …
However, the clinical efficacy of tumour-specific antigens is still challenging. Twelve …
Development of novel self-assembled vaccines based on tumour-specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via activating …
W Shi, Z Tong, S Chen, Q Qiu, J Zhou… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Vaccines based on tumour-specific antigens are a promising approach for immunotherapy.
However, the clinical efficacy of tumour-specific antigens is still challenging. Twelve …
However, the clinical efficacy of tumour-specific antigens is still challenging. Twelve …
Development of novel self-assembled vaccines based on tumour-specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via activating …
W Shi, H Qian - Immunology, 2023 - Elsevier
Hai Qian | ScienceDirect Skip to main content Elsevier logo Journals & Books Search
RegisterSign in Hai Qian Author information Author information Current affiliation: China …
RegisterSign in Hai Qian Author information Author information Current affiliation: China …